Edinburgh Imaging
Edinburgh Imaging
Contact us

18 Oct 21. Edinburgh Imaging Radiochemistry - SALTIRE II

As the Edinburgh Imaging Radiochemistry facility temporarily closes for refurbishment, we look back at the facility's success with the SALTIRE II clinical trial.

Example of (A) non-contrast computed tomography (CT) & aortic valve calcium (AVC) score, (B) 2-dimensional & Doppler echocardiography of peak aortic jet velocity (Vmax), & (C) CT angiography (left hand panels) & 18F-sodium fluoride maximum target to background ratio (TBRmax) uptake on positron emission tomography & CT angiography (right hand panels) at each study timepoint in a single representative participant. Note the enhanced anatomical definition with contrast-enhanced CT compared to echocardiography & non-contrast CT, & the increased confluence of valve calcification in regions of 18F sodium fluoride uptake.
Example of (A) non-contrast computed tomography (CT) & aortic valve calcium (AVC) score, (B) 2-dimensional & Doppler echocardiography of peak aortic jet velocity (Vmax), & (C) CT angiography (left hand panels) & 18F-sodium fluoride maximum target to background ratio (TBRmax) uptake on positron emission tomography & CT angiography (right hand panels) at each study timepoint in a single representative participant. Note the enhanced anatomical definition with contrast-enhanced CT compared to echocardiography & non-contrast CT, & the increased confluence of valve calcification in regions of 18F sodium fluoride uptake.

The Edinburgh Imaging Radiochemistry facility was opened in 2010 & currently houses a cyclotron with supporting radiochemistry suites to create both GMP & research PET radiotracers.

The EI Radiochemistry facility has now temporarily closed for refurbishment.

SALTIRE II: bisphosphonates & RANKL inhibition in aortic stenosis, is a randomised controlled trial which uses imaging as a primary outcome endpoint, plus other imaging endpoints for secondary outcomes. 

The Edinburgh Imaging Facility QMRI carries out the CT calcium scoring, which is the primary outcome endpoint.

The Edinburgh Imaging Radiochemistry facility produces 18F-NaF for PET-CT imaging of the vasculature for one of the secondary outcomes.

 

Image from Pawade T, et al. Effect of denosumab or alendronic acid on the progression of aortic stenosis. A double-blind randomized controlled trial. Circulation. 2021 Apr 29. https://doi.org/10.1161/CIRCULATIONAHA.121.053708

 

 

 

 

 

Relevant links

 

Social media tags & titles

As the Edinburgh Imaging Radiochemistry facility temporarily closes for refurbishment, we look back at the facility's success with the SALTIRE II clinical trial.

@EdinUniMedicine @EdinburghBQ @MarcDweck @EdinUniCVS 

This article was published on